From biosimilars to breakthroughs: regulatory convergence toward evidence-efficient development of monoclonal antibodies

1 Introduction: biosimilars as the regulatory proof-of-concept

Over the past decade, regulatory science governing monoclonal antibody development has undergone a fundamental transformation. Long-standing empiricism-driven paradigms—characterized by extensive animal toxicology programs and large comparative clinical efficacy trials—are being replaced by evidence-efficient, mechanism-based frameworks grounded in analytical rigor, pharmacological understanding, and human-relevant biology. This transition did not arise spontaneously within innovator drug development. Instead, it emerged incrementally through regulatory experience accumulated during the development, review, and post-approval surveillance of biosimilar monoclonal antibodies.

Monoclonal antibodies represent the fastest-growing class of biological therapeutics, with approvals spanning oncology, immunology, neurology, metabolic disease, and infectious disorders (Walsh, 2018; Crescioli et al., 2024). Their clinical success reflects a convergence of molecular and pharmacological attributes, including high target specificity, modular immunoglobulin architecture, predictable pharmacokinetics mediated by neonatal Fc receptor recycling, and well-characterized structure–function relationships (Beck et al., 2010; Mould and Meibohm, 2016). These same attributes rendered monoclonal antibodies uniquely amenable to regulatory frameworks based on molecular comparability rather than empirical redundancy.

The introduction of biosimilar monoclonal antibodies created an unprecedented natural experiment in regulatory science. Unlike novel chemical entities, biosimilars are explicitly anchored to a reference product whose safety, efficacy, and clinical behavior are already established in humans. This reference dependence allowed regulators to empirically assess whether traditional development requirements—particularly animal toxicology studies and comparative clinical efficacy trials—contributed independent, decision-relevant information once high analytical similarity and pharmacokinetic equivalence were demonstrated. Across jurisdictions and across products, accumulated regulatory experience consistently shows that they did not.

Retrospective analyses of biosimilar submissions in both the European Union and the United States revealed that animal toxicology studies routinely reproduced known class effects or target-mediated pharmacology already documented for the reference product, without identifying novel safety signals predictive of human outcomes in the reviewed cohorts (van Meer et al., 2012; Niazi, 2022). Similarly, comparative clinical efficacy trials uniformly confirmed conclusions already established through analytical characterization and pharmacokinetic comparison, without altering regulatory decisions or identifying clinically meaningful differences between products in the programs analyzed (Christl et al., 2017; Kurki et al., 2017). Importantly, no biosimilar approval has been denied based on discordant clinical efficacy results when robust analytical similarity and pharmacokinetic equivalence were demonstrated—a consistent pattern across jurisdictions, though it does not preclude the possibility that animal or clinical studies may yield decision-relevant information in specific, well-defined circumstances as discussed in Section 16. As of 2024, more than 60 biosimilar monoclonal antibodies have been approved globally across the FDA, EMA, and WHO prequalification pathways; across this entire cohort, regulatory reviews have consistently concluded that comparative clinical efficacy trials did not alter approval decisions once analytical similarity and pharmacokinetic equivalence were robustly established (Food and Drug Administration (FDA), 2024; European Medicines Agency (EMA), 2024).

This empirical record forced a reconsideration of long-standing regulatory assumptions. Rather than functioning as sensitive safeguards, animal toxicology and comparative efficacy studies were revealed to be confirmatory at best and scientifically redundant at worst for monoclonal antibodies. Importantly, this conclusion was not derived from theoretical critique alone but from repeated regulatory experience across multiple products, indications, and jurisdictions. Biosimilars thus functioned as the regulatory proof-of-concept demonstrating that analytical similarity and pharmacological comparability are reliable predictors of clinical performance for monoclonal antibodies.

The passage of the FDA Modernization Act 2.0 in December 2022 transformed this accumulated scientific understanding into statutory authority by removing the legal presumption that animal testing is required before human clinical trials. By replacing the term “animal testing” with the broader concept of “nonclinical tests,” the Act explicitly recognized in vitro, computational, and other human-relevant methodologies as acceptable forms of evidence (FDA, 2022). This legislative change did not mandate the elimination of animal studies but inverted the regulatory burden of proof, requiring scientific justification for their use rather than for their omission.

Subsequent FDA guidances, including the 2025 draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies, formalized the generalization of biosimilar-validated principles to innovator biologics. These guidances emphasize weight-of-evidence approaches grounded in target biology, analytical characterization, accumulated class knowledge, and clinical pharmacology, while explicitly acknowledging that extended animal toxicology programs are often uninformative for monoclonal antibodies. Taken together, these developments confirm that biosimilars were not a regulatory exception but the empirical foundation upon which contemporary antibody regulation is built.

In this context, the evolution of monoclonal antibody regulation reflects a single, coherent trajectory. Biosimilars exposed the scientific limitations of legacy development requirements, enabling regulators to align evidentiary standards with modern analytical and translational science. The result is a unified regulatory framework that applies across both biosimilar and innovator pathways, prioritizing evidence that predicts human outcomes while minimizing redundant, ethically burdensome, and scientifically uninformative testing.

2 Monoclonal antibodies as a platform technology

Monoclonal antibodies differ fundamentally from most other classes of therapeutic proteins in that they constitute a true platform technology rather than a heterogeneous collection of unrelated molecular entities. The majority of therapeutic monoclonal antibodies share a conserved immunoglobulin G scaffold, most commonly IgG1 or IgG4, with highly predictable physicochemical and biological properties. Their modular architecture, comprising variable regions responsible for antigen recognition and constant regions governing effector function and systemic disposition, has enabled standardization of manufacturing processes, analytical characterization, and regulatory expectations across a wide range of therapeutic indications (Beck et al., 2010; Strohl, 2015; Carter and Lazar, 2018).

A defining feature of monoclonal antibodies is their pharmacokinetic behavior. Unlike small molecules or many non-antibody proteins, monoclonal antibodies are not eliminated through hepatic metabolism or renal filtration. Instead, their systemic exposure is predominantly governed by neonatal Fc receptor–mediated recycling, which protects the Fc domain from lysosomal degradation and confers half-lives of 10–30 days (Wang et al., 2008; Mould and Meibohm, 2016). This mechanism produces exposure profiles that are relatively insensitive to classical drug–drug interactions and exhibit limited interpatient variability compared with many other drug classes.

From a regulatory science perspective, these properties have profound implications. The predictability of antibody pharmacokinetics and the extensive accumulation of class-level clinical experience allow regulators to rely on prior knowledge when evaluating new antibody products. This accumulated experience has been explicitly acknowledged in regulatory guidance documents, which emphasize that monoclonal antibody behavior can often be anticipated based on shared structural and mechanistic features rather than treated as de novo unknowns (European Medicines Agency, 2012; FDA, 2015; World Health Organization, 2022).

The platform nature of monoclonal antibodies also distinguishes them from other therapeutic proteins such as cytokines, enzymes, peptide hormones, and growth factors. Many of these non-antibody proteins exhibit greater structural diversity, shorter half-lives, and heightened sensitivity to manufacturing-related variability, which complicates extrapolation across products and limits the applicability of class-wide regulatory assumptions (Leader et al., 2008; Walsh, 2018). In contrast, monoclonal antibodies exhibit a degree of architectural conservation that supports regulatory frameworks based on comparability and totality of evidence.

3 Analytical similarity as the primary determinant of clinical performance

The recognition of monoclonal antibodies as a platform technology coincided with significant advances in analytical science that enabled high-precision characterization of these molecules. Modern analytical toolkits enable comprehensive interrogation of critical quality attributes, including primary amino acid sequence, higher-order structure, post-translational modifications, charge heterogeneity, size variants, aggregation propensity, receptor binding, and functional bioactivity (Beck et al., 2013; Berkowitz et al., 2012). These methods are orthogonal, highly sensitive, and capable of detecting molecular differences well below the threshold of clinical detectability.

This analytical resolution has reshaped regulatory thinking about how clinical performance is best predicted. Analytical similarity assessments directly interrogate the molecular attributes that drive pharmacological behavior. In contrast, clinical efficacy endpoints are distal readouts influenced by disease heterogeneity, background therapies, patient adherence, and statistical noise. As a result, clinical efficacy studies are inherently insensitive to subtle molecular differences that fall within the range of acceptable similarity for monoclonal antibodies (Schiestl et al., 2011; Kurki et al., 2017).

Regulatory agencies have increasingly acknowledged this asymmetry in evidentiary sensitivity. Both the FDA and EMA have emphasized that the extent of residual uncertainty remaining after analytical characterization determines the need for additional nonclinical or clinical studies, rather than the automatic application of prescriptive requirements (FDA, 2015; European Medicines Agency, 2012). When analytical similarity is demonstrated comprehensively across relevant quality attributes, the residual uncertainty regarding clinical performance is often minimal.

Table 1 summarizes the core analytical domains and representative methodologies used to establish molecular similarity for monoclonal antibodies. The table illustrates how each analytical domain contributes mechanistically to predicting clinical safety, efficacy, and pharmacokinetics, thereby explaining why analytical data form the evidentiary foundation of evidence-efficient regulatory frameworks. The analytical domains summarized in Table 1 define the molecular evidence base that underpins similarity determinations and increasingly replaces empirical animal and clinical efficacy testing.

TABLE 1. Core analytical domains used to establish molecular similarity of monoclonal antibodies.

Long-standing practices in originator biologic lifecycle management further reinforce the regulatory primacy of analytical similarity. Manufacturing changes introduced after approval are evaluated under the comparability principles established in ICH Q5E, which rely primarily on analytical and functional data to demonstrate that product quality, safety, and efficacy remain unchanged (International Council for Harmonisation, 2004). Clinical efficacy trials are rarely required for such changes, even when multiple manufacturing modifications accumulate over time. This regulatory symmetry exposes a critical logical inconsistency. If analytical comparability is sufficient to ensure clinical continuity for originator products following manufacturing changes, it is scientifically difficult to justify demanding more extensive empirical evidence for biosimilars that demonstrate analytical similarity equivalent to or greater than that of the reference product.

This logic has not remained confined to biosimilar development. As regulators gained confidence in the predictive value of analytical characterization and mechanism-based understanding, these principles naturally informed broader regulatory policy for monoclonal antibodies as a class. Analytical similarity emerged not as a surrogate for clinical evidence, but as a higher-resolution and more scientifically grounded predictor of clinical performance. This recognition laid the groundwork for the subsequent reassessment of animal toxicology and comparative clinical efficacy studies, which is addressed in the following section (Table 1).

4 Foundations of animal toxicology in antibody regulation

Animal toxicology has historically occupied a central position in the development of biological drugs, reflecting regulatory paradigms inherited largely from small-molecule pharmacology. Early guidance documents, including ICH M3 and ICH S6, framed animal studies as presumptively necessary to support first-in-human dosing and to identify potential target organ toxicities before clinical exposure. These frameworks were developed at a time when analytical characterization of biologics was comparatively limited and when mechanistic understanding of antibody-mediated toxicity was incomplete (International Council for Harmonisation (ICH), 2009).

For monoclonal antibodies, however, the scientific assumptions underlying routine animal toxicology have long been problematic. Unlike small molecules, monoclonal antibodies do not form reactive metabolites, do not interact promiscuously with off-target receptors, and do not induce toxicity through nonspecific chemical injury. Instead, antibody-associated adverse effects arise predominantly from exaggerated or unintended pharmacological engagement of the target pathway, immune activation, or downstream physiological perturbations that are highly dependent on human-specific biology (Brennan et al., 2010). These effects are closely tied to target expression patterns, receptor density, signaling context, and immune regulation, all of which vary substantially across species.

As a consequence, the predictive value of animal models for antibody safety has been limited. Even when nonhuman primates are selected as pharmacologically relevant species, differences in immune system regulation, Fc receptor expression, complement activation, and cytokine networks often constrain translational relevance. In addition, the development of anti-drug antibodies in animals frequently confounds the interpretation of repeat-dose toxicology studies, obscuring exposure–response relationships and undermining the ability to distinguish accurate toxicological signals from immunogenic artifacts (van Meer et al., 2012; Prior et al., 2020).

5 Biosimilars as an empirical test of animal toxicology value

The development and regulatory review of biosimilar monoclonal antibodies provided an unprecedented empirical opportunity to evaluate whether animal toxicology studies contribute decision-relevant information. Because biosimilars are explicitly compared to reference products with well-characterized human safety profiles, the incremental value of animal studies could be assessed retrospectively across multiple development programs.

Accumulated regulatory experience has shown that animal toxicology studies for biosimilar antibodies rarely alter regulatory conclusions. Comparative animal studies typically reproduced known class effects or target-mediated pharmacology already documented for the reference product, without identifying novel safety concerns predictive of human outcomes. Retrospective analyses across approved biosimilars confirmed that animal findings did not explain, predict, or meaningfully augment human safety data derived from clinical trials and post-marketing surveillance (van Meer et al., 2012; Niazi, 2022).

More broadly, this observation aligns with contemporary analyses of translational failure in drug development. Large-scale evaluations of preclinical pipelines have shown that animal models exhibit limited concordance with clinical outcomes, even when compounds progress successfully through preclinical testing. Although these analyses span multiple drug classes, they reinforce the conclusion that reliance on animal models as primary predictors of human safety is scientifically fragile, particularly for biologics whose mechanisms are tightly coupled to human-specific pathways (Cook et al., 2014).

Figure 1 illustrates the poor translational concordance between animal toxicology findings and human safety outcomes for monoclonal antibodies, highlighting the mechanistic and species-specific factors that limit predictivity.

6 Regulatory reassessment and legislative codification

The empirical evidence generated through biosimilar development precipitated a gradual but decisive reassessment of animal toxicology requirements by regulatory authorities. Rather than treating animal studies as intrinsic safeguards, regulators increasingly recognized that such studies should be conducted only when they can reduce uncertainty that analytical, mechanistic, or clinical pharmacology data cannot address.

This scientific reassessment was codified legislatively with the passage of the FDA Modernization Act 2.0 in December 2022. The Act removed the statutory requirement for animal testing as a prerequisite for initiating human clinical trials and replaced it with the broader concept of “nonclinical tests,” explicitly encompassing in vitro assays, computational models, and other human-relevant methodologies. Importantly, the Act did not prohibit animal studies but eliminated the presumption of necessity, thereby inverting the regulatory burden of justification (FDA, 2022).

Following this legislative change, the FDA articulated how non-animal evidence could be operationalized through guidance. The 2025 draft guidance on streamlined nonclinical safety studies for monospecific monoclonal antibodies explicitly states that extended animal toxicology programs are generally not warranted when supported by a structured weight-of-evidence assessment incorporating target biology, analytical characterization, accumulated class experience, and clinical pharmacology. The guidance further identifies circumstances in which animal studies may be omitted entirely, including when no pharmacologically relevant species exists or when animal data are confounded by immunogenicity.

Table 2 summarizes the convergent positions of major regulatory authorities regarding the conditional role of animal toxicology in monoclonal antibody development. The table situates FDA policy within a broader international context, demonstrating that regulatory convergence is driven by shared scientific conclusions rather than jurisdiction-specific policy shifts.

TABLE 2. Regulatory positions on animal toxicology for monoclonal antibodies.

7 Generalization from biosimilars to innovator antibodies

A critical implication of this regulatory evolution is that the scientific limitations of animal toxicology are not unique to biosimilars. The same biological principles that constrain the predictability of biosimilar antibodies apply equally to innovator monoclonal antibodies, particularly those targeting well-characterized pathways with established human biology. Biosimilars thus served not as an exception but as the proving ground through which regulators validated evidence-efficient approaches that could be generalized across the antibody class (Table 2).

This generalization represents a fundamental inflection point in biological regulation. It confirms that safety is not generated by the Act of testing itself but by the generation of decision-grade evidence that predicts human outcomes. For monoclonal antibodies, such evidence increasingly resides in analytical characterization, mechanistic understanding of target biology, and clinical pharmacology rather than in routine animal toxicology.

The scientific inconsistency of maintaining separate evidentiary standards for biosimilars and reference biologics, despite identical molecular mechanisms and clinical targets, has been examined in detail in critiques of class-based regulatory differentiation (Niazi, 2022a).

8 Origins and intended role of comparative clinical efficacy studies

Comparative clinical efficacy studies were incorporated into early biosimilar regulatory frameworks as a conservative safeguard intended to confirm that molecular similarity translated into equivalent therapeutic outcomes in patients. When biosimilar pathways were first established, regulators faced legitimate uncertainty about whether subtle differences arising from independent manufacturing processes could translate into clinically meaningful differences in efficacy or safety. In that context, comparative efficacy trials were viewed as a prudent means of reducing residual uncertainty and reinforcing confidence in regulatory decisions (European Medicines Agency, 2012; FDA, 2015).

However, the scientific objectives and evidentiary resolution of comparative clinical efficacy studies differ fundamentally from those of analytical and pharmacokinetic assessments. Clinical efficacy trials are designed to demonstrate non-inferiority within predefined margins for clinical endpoints that are distal to the drug’s molecular attributes. Disease heterogeneity, background therapies, patient adherence, placebo effects, and temporal variability in disease progression influence these endpoints. As a result, comparative efficacy trials are statistically and biologically insensitive to the subtle molecular differences that define biosimilarity for monoclonal antibodies (Schiestl et al., 2011; Kurki et al., 2017).

This inherent limitation becomes particularly salient when analytical characterization has already established high similarity across critical quality attributes. Analytical methods directly interrogate the molecular determinants of pharmacological behavior, whereas clinical endpoints provide low-resolution, aggregated readouts of complex biological systems. Consequently, comparative clinical efficacy studies are poorly suited to function as discriminating tools once analytical and pharmacokinetic similarity have been demonstrated.

A clinically instructive illustration of the ongoing importance of analytical monitoring comes from post-approval experience with trastuzumab biosimilars. Reports of antibody-dependent cell-mediated cytotoxicity (ADCC) drift in manufactured lots demonstrated that analytical characterization could detect functionally meaningful changes that would not be captured by a one-time clinical equivalence study conducted at approval. This case reinforces that the value of analytical characterization is not limited to initial regulatory approval but extends to post-market surveillance and lot-release testing. Evidence-efficient regulation therefore encompasses not only the replacement of confirmatory clinical trials with robust analytical comparisons at the time of authorization, but also requires ongoing analytical quality oversight to detect drift that may affect product performance in patients (Pivot et al., 2019; Schiestl et al., 2017).

9 Empirical evidence from biosimilar development programs

As biosimilar monoclonal antibodies progressed from theoretical constructs to approved therapeutic products, regulators built an extensive empirical record to evaluate the relevance of comparative clinical efficacy studies. Retrospective analyses of regulatory submissions in both the European Union and the United States demonstrated that comparative efficacy trials consistently confirmed conclusions already established through analytical characterization and pharmacokinetic comparison, without altering regulatory outcomes (Christl et al., 2017; Kurki et al., 2017).

The lack of discriminatory power of comparative clinical efficacy and pharmacodynamic studies once analytical similarity is demonstrated has been examined systematically, with proposals for conditional or complete removal of such studies when residual uncertainty is low (Niazi, 2023).

Notably, no biosimilar monoclonal antibody has been denied approval based on discordant comparative clinical efficacy results when robust analytical similarity and pharmacokinetic equivalence were demonstrated. Conversely, no biosimilar has been approved on the strength of comparative efficacy data that contradicted analytical findings. This asymmetry underscores a critical regulatory reality: comparative clinical efficacy studies have not served as independent decision-making tools but rather as confirmatory exercises with limited informational yield.

Figure 2 illustrates the relative discriminatory power of analytical characterization, clinical pharmacokinetics, and comparative clinical efficacy endpoints. The figure depicts analytical similarity as the highest-resolution tier of evidence, pharmacokinetics as an intermediate integrative measure, and clinical efficacy as the lowest-resolution, most variable endpoint.

10 Statistical and biological constraints of clinical endpoints

The limited utility of comparative clinical efficacy studies stems from both statistical and biological constraints. Non-inferiority margins must be sufficiently wide to accommodate expected clinical variability, thereby reducing sensitivity. In chronic and immune-mediated diseases, disease heterogeneity and fluctuating baseline activity further dilute the ability of clinical endpoints to detect subtle differences between products. In oncology, evolving standards of care and combination regimens introduce additional confounding variables that obscure product-specific effects (Weise et al., 2012).

Moreover, clinical efficacy endpoints often do not directly reflect the molecular mechanism of action of monoclonal antibodies. When therapeutic effects are mediated through receptor occupancy, signal modulation, or immune effector functions, pharmacokinetic parameters or validated pharmacodynamic biomarkers may provide more direct and sensitive indicators of biological equivalence than downstream clinical outcomes. In such cases, comparative efficacy trials add noise rather than clarity to the regulatory decision-making process.

These limitations are not merely theoretical. The uniform success of comparative efficacy trials across biosimilar development programs, coupled with their failure to identify clinically meaningful differences, demonstrates that such trials lack the discriminatory power required to resolve residual uncertainty once analytical and pharmacokinetic similarity have been established.

11 Regulatory recognition and evolution toward waiver pathways

In response to this accumulated evidence, regulatory agencies have progressively re-evaluated the role of comparative clinical efficacy studies. Both the FDA and EMA have emphasized that clinical studies should be conducted only when they can address specific, scientifically justified questions that cannot be resolved by analytical or pharmacokinetic data alone (FDA, 2015; European Medicines Agency, 2012) (Table 3).

TABLE 3. Scenarios in which comparative clinical efficacy studies may remain justified.

This evolution culminated in updated FDA guidance articulating a structured framework for assessing the need for comparative efficacy studies. Central to this framework is the concept of residual uncertainty: sponsors and regulators are encouraged to evaluate whether uncertainty remains after comprehensive analytical, functional, and pharmacokinetic assessment, and whether a clinical efficacy study would be capable of resolving that uncertainty. When residual uncertainty is low, comparative efficacy studies are no longer treated as default requirements but as conditional tools applied selectively based on scientific necessity (FDA, 2019).

Table 3 delineates scenarios in which comparative clinical efficacy studies may remain scientifically justified, such as products lacking sensitive pharmacodynamic markers, antibodies with complex or poorly characterized mechanisms of action, or cases in which immunogenicity may differentially affect long-term clinical performance. The table also clarifies product categories that fall outside routine waiver pathways, including vaccines and polyclonal antibody preparations, which are governed by distinct regulatory paradigms. It also shows scientific boundary conditions under which comparative efficacy studies may still reduce residual uncertainty.

12 Extension of waiver logic beyond biosimilars

The regulatory rationale for waiving comparative clinical efficacy studies does not terminate at biosimilar development. The scientific principles underlying these waivers—analytical primacy, mechanism-based prediction, and resolution of residual uncertainty—apply equally to innovator monoclonal antibodies in appropriate contexts. As regulators accumulated confidence in these principles through biosimilar experience, they were increasingly generalized to novel antibody programs, particularly those targeting well-characterized pathways with established human biology.

This continuity reinforces a central thesis of the present review: comparative clinical efficacy studies were not deemphasized because biosimilars are exceptional, but because the scientific rationale for such studies was found to be weak for monoclonal antibodies as a class. Biosimilars provided the empirical foundation for demonstrating this conclusion conclusively, enabling a coherent and unified regulatory framework that prioritizes evidence predictive of human outcomes over tradition-driven testing requirements.

13 Emergence of new approach methodologies in antibody development

The regulatory reassessment of animal toxicology and comparative clinical efficacy studies has coincided with rapid scientific advances that provide credible, decision-relevant alternatives to traditional in vivo testing. Collectively described as new approach methodologies, these tools encompass advanced in vitro systems, human-derived cellular and tissue models, microphysiological platforms, organoids, and increasingly sophisticated computational and artificial intelligence–based modeling frameworks. Their emergence has enabled regulatory authorities to operationalize evidence-based principles validated empirically through biosimilar development (Prior et al., 2020; Cook et al., 2014).

For monoclonal antibodies, the scientific rationale for NAMs is particularly compelling. Particular interactions with human targets drive antibody pharmacology, and toxicity is overwhelmingly mechanism-based rather than chemically mediated. Human-relevant systems therefore, frequently provide greater predictive value than animal models, which are constrained by interspecies differences in target expression, immune regulation, Fc receptor biology, and downstream signaling pathways. Human cell–based assays enable direct interrogation of target engagement, receptor occupancy, effector function, cytokine release, and immune activation in systems that more closely reflect clinical biology (Brennan et al., 2010; Prior et al., 2020).

Figure 3 illustrates the convergence of advanced analytical characterization, human-relevant in vitro systems, and computational modeling into an integrated evidence-efficient development framework. The figure emphasizes that NAMs do not function in isolation but complement analytical and pharmacokinetic assessments to form a coherent, mechanism-driven evidentiary architecture.

14 Role of computational modeling and model-informed development

In parallel with experimental advances, computational modeling has become increasingly central to biological development. Model-informed drug development integrates analytical data, in vitro findings, and early clinical pharmacology to simulate exposure–response relationships, predict human pharmacokinetics, and evaluate safety margins under varying dosing scenarios. For monoclonal antibodies, such models are particularly informative for characterizing target-mediated drug disposition, Fc receptor interactions, and the impact of molecular attributes, such as glycosylation and aggregation, on clearance and exposure (Wang et al., 2008; Mould and Meibohm, 2016).

Regulatory authorities have increasingly recognized that well-constructed and transparently validated models can reduce uncertainty more effectively than traditional animal studies. The FDA has explicitly encouraged the use of modeling and simulation to support dose selection, safety assessment, and study design decisions, reinforcing the transition toward mechanism-based, human-relevant evidence generation (FDA, 2019). When interpreted alongside comprehensive analytical characterization and human in vitro data, computational models provide a robust integrative framework for predicting clinical behavior.

15 Global regulatory convergence toward evidence-efficient frameworks

The shift toward analytics-first, relevance-driven regulation of monoclonal antibodies is not confined to the United States. Regulatory agencies worldwide have converged on similar scientific principles, reflecting shared experience with biosimilars and innovator antibodies. The European Medicines Agency has long emphasized that nonclinical and clinical studies for biosimilar monoclonal antibodies should be conducted only when they provide information not obtainable through analytical and functional comparison (European Medicines Agency, 2012; Noguera Peña and del Castillo Rodríguez, 2021). The World Health Organization, 2022 biosimilar guideline adopts a stepwise, totality-of-evidence approach and explicitly cautions against studies that do not meaningfully reduce uncertainty (World Health Organization, 2022).

Health Canada and Japan’s Pharmaceuticals and Medical Devices Agency have similarly endorsed relevance-driven approaches that prioritize analytical similarity and pharmacokinetic confirmation while minimizing non-informative animal and clinical studies when scientifically justified. These positions reflect not policy alignment for its own sake but convergence driven by shared scientific conclusions regarding the predictive value of analytical and pharmacological evidence (Figure 4).

The operationalization of generally accepted scientific knowledge as a formal regulatory decision tool has been proposed as a mechanism to translate accumulated class experience and analytical understanding into evidence-efficient approval pathways (Niazi, 2023a) (Table 4).

TABLE 4. Global convergence of evidence-efficient regulatory expectations.

Table 4 presents a comparison of regulatory expectations across major jurisdictions for nonclinical safety assessment and clinical confirmation of monoclonal antibodies. The table highlights the degree of international harmonization and demonstrates that evidence-efficient regulation is increasingly the global norm rather than an isolated regional innovation. Table 4 highlights international alignment toward analytics-first and pharmacology-driven regulation of monoclonal antibodies.

16 Scientific boundaries and exceptions to streamlined regulation

Despite this convergence, regulators have been careful to delineate the scientific boundaries of evidence-efficient development. Not all biological products are amenable to streamlined approaches. Polyclonal antibody preparations, vaccines, and plasma-derived products exhibit inherent heterogeneity that precludes comprehensive analytical characterization and therefore fall outside the biosimilar paradigm. Similarly, complex modalities such as antibody–drug conjugates, bispecific antibodies, and multispecific constructs expand the critical quality attribute space and may require additional characterization or targeted clinical evaluation.

These exceptions do not undermine the evidence-efficient framework but instead define its scope of applicability. The governing regulatory principle is proportionality: empirical studies are warranted when they address genuine residual uncertainty that cannot be resolved through analytical, mechanistic, or pharmacokinetic evidence. Conversely, when uncertainty is low and predictability is high, redundant testing imposes ethical, economic, and scientific costs without enhancing patient safety.

17 Toward a unified regulatory model for innovator and biosimilar antibodies

The convergence of biosimilar experience, legislative reform, scientific advancement, and global regulatory alignment supports a unified regulatory model for monoclonal antibody development that applies across both innovator and biosimilar pathways. In this model, comprehensive analytical characterization establishes molecular identity and similarity; human-relevant in vitro systems and computational tools provide mechanistic insight; and clinical pharmacokinetic studies serve as the primary in vivo confirmation of comparable exposure and behavior.

This integrated approach reflects the culmination of a regulatory evolution that began with biosimilars but now encompasses antibody development as a whole. It aligns regulatory requirements with contemporary scientific understanding, replacing prescriptive, tradition-driven testing with evidence-driven decision-making grounded in human biology. The economic, ethical, and access implications of this transformation are addressed in the final section.

18 Economic consequences of evidence-efficient antibody regulation

The transition toward evidence-efficient regulatory frameworks for monoclonal antibodies has substantial economic implications for both biosimilar and innovator development programs. Traditional biologic development paradigms, which relied heavily on extended animal toxicology studies and large comparative clinical efficacy trials, imposed high cost and time burdens that were often disproportionate to their scientific value. Published analyses have estimated that biosimilar development costs historically ranged from approximately 100–250 million US dollars per program, with a large fraction attributable to clinical trials that ultimately served confirmatory rather than discriminating roles (DiMasi et al., 2016; Mulcahy et al., 2018).

As regulatory authorities have increasingly accepted analytical similarity and pharmacokinetic equivalence as the principal determinants of biosimilarity, development timelines and costs have declined. Evidence-efficient pathways reduce the need for large patient populations, shorten development cycles, and lower barriers to market entry. These reductions have tangible market consequences; however, it should be recognized that biosimilar market entry and price dynamics are governed by multiple interacting factors beyond regulatory requirements alone. Adoption barriers including originator lifecycle management strategies, misaligned payer and prescriber incentives, and lack of automatic substitution policies have consistently been identified as primary determinants of biosimilar uptake and price erosion in major markets, as documented extensively in the IQVIA report “Assessing the Biosimilar Void in the US” and corroborated by European experience. Europe experienced substantial biosimilar price erosion, and in some therapeutic areas shortages, prior to recent regulatory streamlining, underscoring that market outcomes are not primarily driven by regulatory pathway design. The claim made here is therefore more limited and precise: jurisdictions with more permissive analytical-based regulatory standards have experienced lower development cost burdens, which contribute to a more favorable economic environment for manufacturer entry, but regulatory streamlining alone is neither sufficient nor the principal driver of competitive pricing (Moorkens et al., 2017; Cohen et al., 2023).

For innovator monoclonal antibodies, similar economic dynamics apply. Streamlined nonclinical safety programs and model-informed development strategies enable more rational allocation of resources toward questions that are genuinely novel or uncertain. By reducing reliance on redundant empirical testing, evidence-efficient frameworks improve development productivity and mitigate one of the primary drivers of pharmaceutical R&D attrition and cost inflation (Kola and Landis, 2004; DiMasi et al., 2016).

Table 5 contrasts traditional and evidence-efficient development paradigms across key economic dimensions, including development timelines, costs, clinical trial burden, and market entry dynamics. It also shows the practical consequences of legacy versus modern regulatory paradigms.

TABLE 5. Economic and Access implications of evidence-efficient vs. Traditional development.

19 Ethical dimensions of reducing redundant testing

The ethical implications of evidence-efficient regulation extend beyond economics. Animal testing, particularly in nonhuman primates, raises persistent ethical concerns related to animal welfare, scientific justification, and societal expectations. When animal studies fail to provide predictive or decision-relevant information, their continued use cannot be ethically justified under the principles of replacement, reduction, and refinement that guide modern biomedical research ethics (Prior et al., 2020).

Similarly, comparative clinical efficacy trials conducted solely to satisfy regulatory convention raise ethical concerns regarding patient exposure to unnecessary research risks. Patients enrolled in such trials may be subjected to invasive procedures, placebo exposure, or delayed access to effective therapies without a commensurate increase in scientific knowledge or patient benefit. The recognition that many comparative efficacy studies lack discriminatory power once analytical and pharmacokinetic similarity have been established reinforces the ethical imperative to restrict such trials to situations in which they can meaningfully reduce uncertainty (Christl et al., 2017).

Evidence-efficient regulatory frameworks, therefore, align ethical responsibility with scientific rigor. By prioritizing evidence that predicts human outcomes and minimizing redundant testing, regulators can reduce unnecessary harm while maintaining high standards of patient safety.

20 Implications for global access and health equity

The consequences of regulatory streamlining are particularly significant for global access to biological therapies. High development costs and prolonged timelines disproportionately limit access to monoclonal antibodies in low- and middle-income countries, where healthcare budgets are constrained, and originator products may be unaffordable for large segments of the population. The World Health Organization has identified biosimilars as a critical mechanism for expanding access to essential biologic medicines, provided that regulatory requirements are scientifically justified and proportionate (World Health Organization, 2022).

Evidence-efficient regulatory frameworks facilitate broader manufacturer participation in emerging markets, enable technology transfer, and support the development of sustainable local or regional supply chains. It should be noted that while lower regulatory cost burdens can encourage manufacturer participation, the relationship between regulatory streamlining and observed price reductions is not direct or causal in isolation. Supply chain regionalization, as increasingly practiced in the post-pandemic era, may reduce economies of scale and partially offset cost savings from streamlined development. Observational data nonetheless suggest that jurisdictions with more proportionate biosimilar regulatory requirements tend to attract more market entrants, which contributes to competitive pricing dynamics and improved patient access—particularly in settings where adoption incentives and prescriber policies are also aligned (Moorkens et al., 2021; World Health Organization, 2022).

Table 6 identifies product classes that remain outside routine evidence-efficient pathways due to inherent scientific limitations, clarifying that streamlined regulation is not indiscriminate but grounded in clearly defined boundaries. This table clarifies why specific biologic categories remain outside streamlined regulatory frameworks.

TABLE 6. Product classes outside routine evidence-efficient pathways.

21 An integrated regulatory model for innovator and biosimilar antibodies

Synthesizing the evidence presented across this review, a coherent and unified regulatory model for monoclonal antibody development emerges. This model applies across both innovator and biosimilar pathways and is anchored in several interdependent principles. Comprehensive analytical characterization establishes molecular identity, similarity, and control of critical quality attributes. Human-relevant in vitro systems and computational models provide mechanistic insight into pharmacology and safety. Clinical pharmacokinetic studies serve as the primary in vivo bridge, confirming that molecular similarity translates into comparable exposure and behavior in humans. Additional nonclinical or clinical studies are conducted only when residual uncertainty remains that cannot be resolved through these approaches Figure 5. Integrated Regulatory Model for Innovator and Biosimilar Antibodies.

At this point in the manuscript, Figure 5 is introduced as a capstone schematic illustrating the integrated regulatory model for innovator and biosimilar monoclonal antibodies. The figure visually summarizes how analytical, mechanistic, and pharmacokinetic evidence converge to support regulatory decision-making, with empirical studies applied selectively based on scientific necessity.

22 Final conclusions and forward-looking regulatory science questions

The evolution of monoclonal antibody regulation over the past decade represents a paradigm shift in regulatory science. Biosimilars served as the empirical proving ground through which regulators demonstrated that analytical similarity and pharmacokinetic equivalence are reliable predictors of clinical performance. In contrast, animal toxicology and comparative clinical efficacy studies frequently add limited decision-relevant information. The FDA Modernization Act 2.0 codified this scientific understanding into law, and subsequent FDA guidance generalized biosimilar-validated principles to innovator antibodies, completing the transition toward evidence-efficient regulation.

This transformation does not diminish regulatory rigor. On the contrary, it enhances scientific integrity by aligning evidentiary requirements with contemporary understanding of antibody biology and translational predictability. By prioritizing mechanisms, molecular attributes, and human-relevant data, regulators can better predict clinical outcomes while reducing unnecessary testing, ethical burden, and development costs.

Several forward-looking questions remain central to the continued maturation of this framework. As antibody modalities become more complex, how should similarity boundaries be defined and justified for increasingly multidimensional quality attributes? What role should real-world evidence play in validating predictions derived from analytical and pharmacokinetic data? How can international harmonization be sustained as regulatory systems adapt to emerging modalities such as bispecific antibodies and antibodies–drug conjugates? Addressing these questions will require continued investment in regulatory science, transparent data sharing, and sustained collaboration among regulators, developers, and the scientific community.

In sum, the convergence of biosimilar experience, legislative reform, and scientific advancement has reshaped antibody regulation into a coherent, evidence-efficient paradigm. This unified framework provides a sustainable path forward for innovation, global access, and patient safety in the era of complex biological therapeutics.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript. Figures were drawn by BioRender from author's figure description.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Footnotes

Edited by: Yiannis Sarigiannis, University of Nicosia, UNIC Athens, Greece

Reviewed by: Alfonso Noguera, Complutense University of Madrid, Spain

Delphine Dioudonnat-Courmier, Organon, United States